Related references
Note: Only part of the references are listed.Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes
Andrzej Budaj et al.
EUROPEAN HEART JOURNAL (2009)
Anaphylaxis during cardiac surgery: Implications for clinicians
Jerrold H. Levy et al.
ANESTHESIA AND ANALGESIA (2008)
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease
Mark Y. Chan et al.
CIRCULATION (2008)
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor
M. Y. Chan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Bivalirudin during primary PCI in acute myocardial infarction
Gregg W. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Coagulation 2006: A modern view of hemostasis
Maureane Hoffman et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2007)
In vivo response to vascular injury in the absence of factor IX: Examination in factor IX knockout mice
Tong Gui et al.
THROMBOSIS RESEARCH (2007)
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology - A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity
Christopher K. Dyke et al.
CIRCULATION (2006)
Bivalirudin for patients with acute coronary syndromes
Gregg W. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS trial
JH Alexander et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI pilot
JH Alexander et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Antidote-mediated control of an anticoagulant aptamer in vivo
CP Rusconi et al.
NATURE BIOTECHNOLOGY (2004)
Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions
TD Kinnaird et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Myocardial fibrosis in mice with overexpression of human blood coagulation factor IX
A Ameri et al.
BLOOD (2003)
RNA aptamers as reversible antagonists of coagulation factor IXa
CP Rusconi et al.
NATURE (2002)
Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis
JR Toomey et al.
THROMBOSIS RESEARCH (2000)
Share Paper
